MedTwenty
Companies

Tempus

This profile is still being built. It is not yet listed in the company index.

MedTwenty Indices and trackers are editorial indicators and business information. They are not investment, financial, legal or medical advice, and not a regulated benchmark.

Summary

Sequencing-led precision medicine company combining clinical genomic profiling with a large real-world oncology data asset. Now the acquirer of Personalis and a direct competitor to Foundation Medicine in comprehensive genomic profiling.

Finances

Not published (small company accounts)

Timeline

No verified timeline entries yet.

MedTwenty coverage